Free tools Windows power users keep installed
One-click scans. No signup required.
The claim that Twist Bioscience’s consensus price target rose 12.94% to €108.63 is not confirmed by the available sources. Twist’s own analyst-coverage page says its consensus data was last updated November 20, 2025; it does not verify that later euro-denominated figure or its reported increase. A separate 2026 report of a Guggenheim target change is an individual US-dollar estimate, not confirmation of the claimed consensus.
What is known about the €108.63 figure?
The exact €108.63 target, the 12.94% increase, the date of the change, and the prior value used to calculate the increase are not established by the available sources. Twist Bioscience’s analyst-coverage page reports that its consensus data was last updated November 20, 2025, so that disclosure cannot substantiate a later revision. The figure should therefore be treated as an unverified claim, not as a confirmed current consensus or share price. Twist analyst coverage
What does Twist mean by analyst consensus?
Twist says the figures in its consensus tables are “a simple arithmetic average of the most recent forecasts that have been provided to Twist.” The company says the estimates are not weighted for recency or individual analysts and that submissions have not been adjusted to exclude any. That means the published measure is an average, not necessarily the median, and it may not reflect a uniform forecast date or a fixed analyst set. Twist Investor Relations
Twist also says the estimates represent analysts’ opinions, not the company’s own view, and that it does not endorse or concur with those forecasts. The company says it has not verified the information and warns that forward-looking estimates involve risks and uncertainty. Analyst coverage lists firms following Twist, but coverage alone does not show which analysts contributed forecasts to a particular consensus calculation. Twist analyst coverage
The Tool Desk
Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →#1 Best Overall
How does the reported Guggenheim revision differ?
Benzinga reports a 2026 Guggenheim target change for Twist Bioscience from $107 to $212. Those are US-dollar figures for one analyst’s target; they are not the claimed €108.63 consensus. A single analyst revision and a change in an average across multiple analysts are different measures, and the reported dollar figures do not establish the euro claim. Benzinga analyst targets
What would be needed to verify a consensus-target change?
A reliable account of the claimed revision would need a source that identifies the report date and currency, confirms that €108.63 is a consensus rather than an individual target, and states how the consensus was calculated. It should also identify the contributing analyst count or set, the prior consensus value behind the 12.94% calculation, and the target horizon. Without those details, the percentage cannot be independently checked or compared fairly with another estimate.
Rank #2
- Ideal for Gifting
- Ideal for a bookworm
- Compact for travelling
A price target is an analyst forecast, not a promised share price, company guidance, or a prediction that the stock will reach that level. Twist’s estimates are explicitly presented as external analyst opinions, and the company disclaims verification and endorsement. Twist Investor Relations
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What does Twist Bioscience do?
Twist is a synthetic-biology company that makes DNA on silicon chips. Its product and service areas include synthetic genes, next-generation sequencing sample-preparation tools, antibody libraries, oligo pools, synthetic controls, and antibody-discovery services. Its customers and applications span research, drug discovery, disease detection, gene editing, industrial chemicals, and agriculture, rather than consumer products. Twist product information Twist FY2025 Form 10-K
In its FY2025 filing, Twist describes a platform capable of writing more than 1,000,000 oligonucleotides up to 500 bases on each silicon chip, and estimates a 99.8% reduction in chemicals used per gene compared with plate-based synthesis. These are company-reported descriptions and estimates, not independent performance testing. Twist FY2025 Form 10-K
Quick Recap
Best Value
- It can be a gift option
- Comes with secure packaging
- Helpful in various ways
Rank #4
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
